Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

Medicine, Oncology, Cancer Pharmacology +12

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · New England Journal of Medicine · 2009 · 8.2K citations · Full text

Medicine, Oncology, Pharmacology +13

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine · 2005 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +15

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Nick Thatcher, Alex Y. Chang, Purvish M. Parikh et al. · The Lancet · 2005 · 2.1K citations

Medicine, Oncology, Palliative Oncology +9

Role of <i>KRAS</i> and <i>EGFR</i> As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

Chang‐Qi Zhu, Gilda da Cunha Santos, Keyue Ding et al. · Journal of Clinical Oncology · 2008 · 665 citations · Full text

Medicine, Molecular Genetics, Oncology +17